Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Mitomics, Sterling Pathology National Laboratories; J. Craig Venter Institute, CLC Bio; LabCorp

NEW YORK (GenomeWeb News) – Mitomics said this week it has entered into a sales and marketing deal with Sterling Pathology National Laboratories covering Mitomics' Prostate Core Mitomic Test. Sterling will make the test available throughout the US on a non-exclusive basis. Further terms were not disclosed.


The J. Craig Venter Institute has extended its site license agreement with CLC Bio through 2017. JCVI has used CLC Bio's enterprise platform since 2009 including for its work as part of the Human Microbiome Project.


Laboratory Corporation of America Holdings said its Biorepository has been accredited by the College of American Pathologists. LabCorp opened the Biorepository in 2009 and offers well-annotated, consented specimens for biomarker discovery research.


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.